Georgia's Online Cancer Information Center

Find A Treatment Site

Winship Cancer Institute of Emory University

Winship Cancer Institute NCI Designated Comprehensive Cancer Center
Winship Cancer Institute of Emory University
Atlanta, Georgia

Winship Cancer Institute of Emory University is Georgia's first and only comprehensive cancer center designated by the National Cancer Institute (NCI). Designation requires meeting rigorous criteria for the depth and breadth of basic science and clinical research, in addition to cancer prevention, control, and population/behavioral sciences. It requires effective collaboration among various disciplines and with community partners in private practice and in academic centers throughout Georgia and across the nation. With this recognition comes the responsibility to provide public information, education and outreach to other health care professionals and the community. NCI designation for Winship gives Georgians improved access to clinical trials and resources that may not be available elsewhere.

The Winship Cancer Institute (Winship) at Emory University is a multidisciplinary matrix center that supports, facilitates, coordinates, and centralizes cancer research, quality oncology care, education, and dissemination at Emory University and its affiliate institutions in order to reduce the burden of cancer, associated morbidity, and mortality in the state of Georgia, the Southeastern region, and the U.S. Winship is dedicated to the integration of innovative clinical and basic science research with outstanding patient care for the prevention, treatment and control of cancer.

1-888-946-7447
winshipcancer.emory.edu

Treatment Sites in Georgia

Primary Location

1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-1900 (p)
winshipcancer.emory.edu

driving directions

Doctors

Nazmi Volkan Adsay MD
Michael R. Aho MD
Mehmet Akce MD
Mehrdad Alemozaffar MD
Olatunji B. Alese MD
Olatunji B. Alese MD
Pamela Blair Allen MD, MSc
Ana Antun MD
Jack Arbiser MD, PhD
Cletus A. Arciero MD
Martha L. Arellano MD
Bruce J. Barron MD
Deborah A. Baumgarten MD, MPH
Jonathan J. Beitler MD, MBA, FACR
Leon Bernal MD
George G. A. Birdsong MD
William G. Blum
Daniel J. Brat MD, PhD
Otis W. Brawley MD
Joan Cain MD, MSc
Grant W. Carlson MD
Bradley C. Carthon, MD, PhD
Amy Y. Chen MD
Cynthia Cohen MD
Jonathon B Cohen MD, MS
Michael A. Cohen MD, FACR
Laronna S Colbert MD
Ian R. Crocker MD, FACR
Walter J Curran, Jr. MD, FACR
Keith A. Delman MD, FACS
Maria Diab MD
Roberto R. Diaz MD
Scott H. Edelman MD
John William Eley MD, MPH
Bassel F El-Rayes MD
Tony Y Eng MD
Christopher R. Flowers MD
Sarah Friend MD
Sheryl A. Gabram-Mendola MD, MBA, FACS
Manila Gaddh , MD
Anthony Andrew Gal MD
Jacques Galipeau MD
Karen D. Godette MD
Keerthi Gogineni MD
Bruce D Goldsweig MD
Cathy L Graham MD, FACS
William J. Grist MD
Kathleen Gundry MD
Vikas A Gupta MD
Raghuveer K. Halkar MD
Chunhai Hao MD, PhD
Wayne B. Harris MD
R. Donald Harvey , PharmD
Natalyn N. Hawk MD
Leonard T. Heffner Jr., MD
Bruce W. Hershatter MD
Kristin Higgins MD
Charles E. Hill MD
Craig C Hofmeister MD, MPH
Chad A. Holder MD
Stephen B. Hunter MD
Sol Jacobs MD
Ashesh B. Jani MD
David L. Jaye MD
Jade Jones MD
Jonathan L. Kaufman MD
H. Jean Khoury MD, FACP
Kevin Kim MD
Adam M. Klein MD
Rebecca Bruner Klisovic MD
Jean L Koff MD
David A. Kooby MD
Vamsi K. Kota MD
Joan Kramer
Omer Kucuk MD
Ragini R Kudchadkar MD
J. David Lambeth MD, PhD
Jerome C. Landry MD
Amelia A. Langston MD
Stephen K. Lau MD
David H. Lawson MD
Mary Jo Lechowicz MD
Daniel J. Lee MD
Melinda Moore Lewis MD
Shiyong Li MD, PhD
Jolinta Y Lin MD
James V. Little MD
Sagar Lonial MD
Shishir K. Maithel MD
Anant Mandawat MD
Karen P. Mann MD, PhD
Viraj Master MD, PhD
Mark William McDonald MD
Morgan L. McLemore MD
Jane L Meisel MD
Daniel L. Miller MD
Leon Bernal- Mizrachi MD
David K Monson MD
Melvin Moore MD
Mario Mosunjac MD
Susan C. Muller DMD, MS
Padma C. Nadella MD
Mary S. Newell MD
Peter T. Nieh MD
Ajay K. Nooka MD, MPH
William O'Connell MD
Kenneth Ogan MD
Joel A Okoli MD MPH
Jeffrey J. Olson MD
Gabriela M. Oprea MD
Adeboye O. Osunkoya MD, FCAP
Taofeek K. Owonikoko MD
Nelson M. Oyesiku MD, PhD, FACS
Nicki Panoskaltsis MD, PhD, FRCP
Nicki Panoskaltsis MD, PhD, FRCP
Elisavet Paplomata MD
Douglas C. Parker MD
Pretesh Patel MD
Sagar A Patel MD
Allan Pickens MD
Rathi Pillai MD
Brian P Pollack MD, PhD
Suresh S. Ramalingam MD
William Read , MD
Satyanarayan K. Reddy MD
Nickolas B Reimer MD
Maria J. Ribeiro MD
Chad W Ritenour MD
Monica Rizzo MD
Steven M. Roser DMD, MD
Peter J. Rossi MD
Nabil F. Saba MD, FACP
Ruth Sacks MD
Manu S Sancheti
Martin G Sanda MD
Juan M. Sarmiento MD
Neil D Saunders MD
David M. Schuster MD
Judy H. Sequeira MD
Charles W. Sewell MD
Virginia O Shaffer MD
Mihir M Shah MD
Jyotirmay Sharma MD
Dong Moon Shin MD
Hui-Kuo G. Shu MD, PhD
Mark Shumate MD, MPH
Gabriel L. Sica MD
Momin T. Siddiqui MD, FIAC
William C. Small MD
Cyril O. Spann MD,SM, FACOG, FACS
Charles A. Staley MD
Liza J. Stapleford MD
Sidney F. Stein MD
Conor F Steuer
Toncred M. Styblo MD
Preeti D Subhedar MD, MSPT
Pakkala Suchita
Ajay Tadepalli MD
Talaat S. Tadros MD
Ahmad Tarhini MD, PhD
Meena Thirunavu MD
Mylin A. Torres MD
William E. Torres MD
Keriann M. Van Nostrand MD
Vijay Alluri Varma MD
Alfredo D. Voloschin MD
J. Trad Wadsworth MD
Edmund K. Waller MD, PhD, FACP
Mark D Walsh MD, FACS
Carl Washington MD
Sharon W. Weiss MD
Ifor R. Williams MD, PhD
Elliott F. Winton MD
Christina Wu MD
Howa Yeung MD
David Yu MD
Melinda L Yushak
Jim Zhong MD

Clinical Trials in Georgia

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Cancer Type: Hematopoietic Malignancies, Leukemia, Unknown Primary

6-Hour Oxaliplatin in Preventing Nerve Damage in Patients with Advanced or Metastatic Gastrointestinal Cancer
Cancer Type: Unknown Primary

A Beta-only IL-2 ImmunoTherapY Study
Cancer Type: Bile Duct Cancer, Bladder Cancer, Cervical Cancer, Colon/Rectal Cancer, Gallbladder Cancer, Melanoma, Ovarian Cancer, Sarcoma, Stomach/ Gastric Cancer

A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
Cancer Type: Melanoma, Unknown Primary

A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma
Cancer Type: Skin Cancer (Non-Melanoma), Unknown Primary

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
Cancer Type: Multiple Myeloma

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
Cancer Type: Lung Cancer

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Cancer Type: Multiple Myeloma, Plasma cell neoplasm

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Cancer Type: Hematopoietic Malignancies
Study Coordinator: Heather Renfroe - 404-778-5127


A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
Cancer Type: Colon/Rectal Cancer, Ovarian Cancer, Pancreatic Cancer, Stomach/ Gastric Cancer

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
Cancer Type: Gynecologic Cancers, Lung Cancer, Primary Peritoneal Cancer

A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma
Cancer Type: Multiple Myeloma

A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Cancer Type: Leukemia, Lymphoma

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Cancer Type: Melanoma, Unknown Primary

A Robot (My Special Aflac Duck) for the Reduction of Medical Setting Distress in Pediatric Cancer Patients
Cancer Type: Hematopoietic Malignancies, Solid Tumor

A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
Cancer Type: Leukemia, Non-Hodgkin Lymphoma

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
Cancer Type: Hematopoietic Malignancies, Leukemia, Unknown Primary

A Study Combining the Peposertib (M3814) Pill with Standard Chemotherapy in Patients with Ovarian Cancer with an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
Cancer Type: Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
Cancer Type: Unknown Primary

A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
Cancer Type: Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Cancer Type: Breast Cancer, Unknown Primary

A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
Cancer Type: Ovarian Cancer, Solid Tumor, Unknown Primary, Uterine Cancer

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Cancer Type: Multiple Myeloma

A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
Cancer Type: Breast Cancer, Unknown Primary

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Cancer Type: Breast Cancer, Unknown Primary

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Cancer Type: Breast Cancer

A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
Cancer Type: Unknown Primary

A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
Cancer Type: Solid Tumor, Unknown Primary

A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3
Cancer Type: Solid Tumor, Unknown Primary

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Cancer Type: Breast Cancer, Solid Tumor, Unknown Primary

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Cancer Type: Cancer-Related Syndrome, Leukemia

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Cancer Type: Solid Tumor, Unknown Primary

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Cancer Type: Head and Neck Cancer

A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
Cancer Type: Lung Cancer, Lymphoma, Neuroendocrine Tumor, Ovarian Cancer

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary

A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation
Cancer Type: Leukemia

A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
Cancer Type: Bladder Cancer, Unknown Primary

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
Cancer Type: Bladder Cancer, Unknown Primary

A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Cancer Type: Colon/Rectal Cancer, Lung Cancer, Melanoma

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
Cancer Type: Breast Cancer, Unknown Primary

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
Cancer Type: Cervical Cancer

A Study of XMT-1660 in Participants With Solid Tumors
Cancer Type: Solid Tumor, Unknown Primary

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
Cancer Type: Germ Cell Tumor

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Cancer Type: Multiple Myeloma, Plasma cell neoplasm

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Cancer Type: Non-Hodgkin Lymphoma

A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases
Cancer Type: Sarcoma

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
Cancer Type: Bile Duct Cancer

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Cancer Type: Solid Tumor, Unknown Primary

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Cancer Type: Multiple Myeloma

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Cancer Type: Brain & Spinal Cord Tumor

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Cancer Type: Head and Neck Cancer

Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
Cancer Type: Hematopoietic Malignancies, Solid Tumor

Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
Cancer Type: Leukemia

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Cancer Type: Breast Cancer, Unknown Primary

An Investigational Scan (18F-rhPSMA 7.3 PET/CT) with and without Furosemide for the Reduction of Bladder Activity in Patients with Biochemically Recurrent Prostate Cancer
Cancer Type: Prostate Cancer

An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Cancer Type: Pancreatic Cancer

ARX517 as Monotherapy and in Combination Regimens in Subjects With Metastatic Castration-resistant Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
Cancer Type: Breast Cancer

Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
Cancer Type: Leukemia

Biomarker-Driven Radiation Therapy Dose Reduction after Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer
Cancer Type: Head and Neck Cancer, Unknown Primary

BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy
Cancer Type: Liver Cancer / Hepatoblastoma

Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated with Brentuximab Vedotin or Checkpoint Inhibitors
Cancer Type: Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary

Brentuximab Vedotin and Nivolumab with or without Ipilimumab in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Cancer Type: Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary

Canakinumab and Darbepoetin Alfa for the Treatment of Lower-Risk Myelodysplastic Syndromes in Patients Who Have Failed Erythropoietin Stimulating Agents
Cancer Type: Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)

CAR-T Long Term Follow Up (LTFU) Study
Cancer Type: Unknown Primary

Cholecalciferol in Improving Survival in Patients with Newly Diagnosed Cancer with Vitamin D Insufficiency
Cancer Type: Leukemia, Lymphoma

Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients
Cancer Type: Breast Cancer, Unknown Primary

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Cancer Type: Leukemia, Myelodysplastic Syndromes (MDS)

Communication Issues in Patient and Provider Discussions of Immunotherapy
Cancer Type: Solid Tumor

Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy, The Ice Compress Trial
Cancer Type: Solid Tumor

Comparing the Outcome of Standard Systemic Therapy Only versus Standard Systemic therapy with either Surgery or Radiation Therapy, for Patients with Advanced Prostate cancer
Cancer Type: Prostate Cancer , Unknown Primary

Comparison of Surgery to Stereotactic Body Radiation Therapy (SBRT) in Patients With Stage I Non-Small Cell Lung Cancer
Cancer Type: Lung Cancer

Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Cancer Type: Lung Cancer

DALY 2.0 USA/ MB-CART2019.1 for DLBCL
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma with Kidney Failure
Cancer Type: Multiple Myeloma, Plasma cell neoplasm

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Cancer Type: Lung Cancer, Unknown Primary

DECOY20 Study in Patients With Advanced Solid Tumors
Cancer Type: Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer

Docetaxel, Ramucirumab, and Pembrolizumab for the Treatment of Metastatic or Recurrent Non-small Cell Lung Cancer in Patients who have Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade Therapy
Cancer Type: Lung Cancer

Donor Immune Cells (Allogenic Ex Vivo Expanded Gamma Delta T Cells), Dinutuximab, Temozolomide, and Zoledronate for the Treatment of Refractory, Relapsed, or Progressive Neuroblastoma in Children
Cancer Type: Neuroblastoma

Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
Cancer Type: Breast Cancer, Cervical Cancer, Esophogeal Cancer, Head and Neck Cancer, Hodgkin Lymphoma, Lung Cancer, Lymphoma, Stomach/ Gastric Cancer

Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
Cancer Type: Melanoma

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With AML or MDS
Cancer Type: Leukemia, Myelodysplastic Syndromes (MDS)

Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL
Cancer Type: Cancer-Related Syndrome

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
Cancer Type: Solid Tumor

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Cancer Type: Colon/Rectal Cancer, Pancreatic Cancer

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients
Cancer Type: Melanoma

ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study
Cancer Type: Unknown Primary

Enfortumab Vedotin plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
Cancer Type: Bladder Cancer

Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Chemo-Immunotherapy with Pembrolizumab Before Surgery
Cancer Type: Breast Cancer

Evaluation of Human Immune Responses to Vaccination in Patients with Lymphoma
Cancer Type: Hematopoietic Malignancies, Leukemia, Non-Hodgkin Lymphoma

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Cancer Type: Breast Cancer, Unknown Primary

Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Evaluation of Lymphoma Prognosis and Survivorship in Recently Diagnosed Patients, LEO Study
Cancer Type: Hodgkin Lymphoma, Lymphoma, Non-Hodgkin Lymphoma

Evaluation of Sexual Toxicities in Women After Pelvic Radiotherapy
Cancer Type: Anal Cancer, Cervical Cancer, Colon/Rectal Cancer, Gynecologic Cancers, Solid Tumor, Uterine Cancer

Fatigue Assessment in Patients with Breast Cancer Undergoing Chemotherapy, Surgery, or Radiation Therapy
Cancer Type: Breast Cancer, Unknown Primary

Fiber-Rich Foods for the Treatment of Obesity and Prevention of Colon Cancer
Cancer Type: Colon/Rectal Cancer

Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
Cancer Type: Hematopoietic Malignancies

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
Cancer Type: Lung Cancer

First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors
Cancer Type: Solid Tumor, Unknown Primary

First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors
Cancer Type: Solid Tumor, Unknown Primary

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
Cancer Type: Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Lung Cancer, Ovarian Cancer, Stomach/ Gastric Cancer

First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors
Cancer Type: Colon/Rectal Cancer, Pancreatic Cancer

First-in-Human Study of RGT-419B Alone and With Endocrine Therapy in Subjects With HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Cancer Type: Breast Cancer

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Cancer Type: Leukemia

Fluciclovine F18 or Gallium Ga 68-labeled PSMA-11 PET/CT in Enhancing Outcomes in Patients with Prostate Adenocarcinoma
Cancer Type: Prostate Cancer , Unknown Primary

GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies
Cancer Type: Hematopoietic Malignancies, Leukemia, Multiple Myeloma

Genetic Information and Family Testing Platform to Facilitate Genetic Testing for Cancer Patients' Families, GIFT Study
Cancer Type: Solid Tumor

Genetic Testing in Guiding Treatment for Patients with Brain Metastases
Cancer Type: Brain & Spinal Cord Tumor, Solid Tumor, Unknown Primary

Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Cancer Type: Lung Cancer, Unknown Primary

HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Cancer Type: Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary

HPVIQ-PedOnc Intervention in Maximizing HPV Vaccine Uptake in Young Cancer Survivors
Cancer Type: Hematopoietic Malignancies, Solid Tumor

Hypofractionated Proton or Photon Radiation Therapy for the Treatment of Brain Tumors, the HiPPI Study
Cancer Type: Brain & Spinal Cord Tumor

Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients with Glioblastoma
Cancer Type: Brain & Spinal Cord Tumor

ILND Surgery Alone or after Chemotherapy with or without Radiation Therapy in Treating Patients with Advanced Penile Cancer
Cancer Type: Penile Cancer

IMGN853 With Carboplatin in Second-line Treatment of FRa Expressing, Platinum-sensitive Epithelial Ovarian Cancer
Cancer Type: Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults with Newly Diagnosed B Acute Lymphoblastic Leukemia
Cancer Type: Leukemia

International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Cancer Type: Prostate Cancer

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Cancer Type: Breast Cancer

Ketorolac before Surgery for the Treatment of Stage I-II Non-small Cell Lung Cancer or Stage III Renal Cell Cancer
Cancer Type: Lung Cancer

KZR-261 in Subjects With Advanced Solid Malignancies
Cancer Type: Colon/Rectal Cancer, Eye Cancer, Melanoma, Prostate Cancer , Solid Tumor, Unknown Primary

Letrozole with and without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
Cancer Type: Breast Cancer

Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
Cancer Type: Lung Cancer

Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients with Multiple Myeloma
Cancer Type: Bone Tumor, Multiple Myeloma, Plasma cell neoplasm

Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)
Cancer Type: Breast Cancer, Unknown Primary

Metformin for the Prevention of Oral Cancer in Patients with Oral Leukoplakia or Erythroplakia
Cancer Type: Unknown Primary

Mobile Health for Adherence in Breast Cancer Patients
Cancer Type: Breast Cancer, Unknown Primary

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Cancer Type: Leukemia

Modified Immune Cells (Autologous iC9.GD2.CAR.IL-15 T cells) for Treating Patients with Relapsed or Refractory High Risk Neuroblastoma, Ganglioneuroblastoma, or Osteosarcoma
Cancer Type: Neuroblastoma, Neurologocal Tumor, Sarcoma

NAUTILUS: OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)
Cancer Type: Melanoma

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Cancer Type: Hematopoietic Malignancies, Melanoma

Niraparib and Panitumumab in Treating Patients with Advanced or Metastatic Colorectal Cancer
Cancer Type: Colon/Rectal Cancer, Unknown Primary

Nivolumab in Treating Patients with Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Cancer Type: Hematopoietic Malignancies, Solid Tumor

NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
Cancer Type: Leukemia, Myelodysplastic Syndromes (MDS)

Obinutuzumab with or without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients with Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Observation or Radiation Therapy in Treating Patients with Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Cancer Type: Brain & Spinal Cord Tumor

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Cancer Type: Breast Cancer, Ovarian Cancer

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
Cancer Type: Breast Cancer

Oral EPI-7386 in Patients With Castration-Resistant Prostate Cancer
Cancer Type: Prostate Cancer

Osimertinib in Treating Patients with Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Cancer Type: Lung Cancer

Palliative Radiotherapy with Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer
Cancer Type: Lung Cancer

Paricalcitol and Hydroxychloroquine in Combination with Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced or Metastatic Pancreatic Cancer
Cancer Type: Pancreatic Cancer, Unknown Primary

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
Cancer Type: Skin Cancer (Non-Melanoma), Unknown Primary

Pembrolizumab with and without Intra-operative Radiation Therapy in Treating Patients with Triple Negative Breast Cancer
Cancer Type: Breast Cancer

Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients with Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer
Cancer Type: Stomach/ Gastric Cancer

PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Cancer Type: Lung Cancer, Prostate Cancer

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Cancer Type: Head and Neck Cancer, Sarcoma, Solid Tumor

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Cancer Type: Colon/Rectal Cancer, Pancreatic Cancer, Sarcoma, Solid Tumor

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Cancer Type: Colon/Rectal Cancer, Melanoma, Ovarian Cancer

Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma
Cancer Type: Multiple Myeloma

Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors
Cancer Type: Brain & Spinal Cord Tumor, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Solid Tumor, Unknown Primary

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
Cancer Type: Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
Cancer Type: Breast Cancer, Unknown Primary

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
Cancer Type: Lung Cancer

Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients with IDH Mutant Grade II or III Glioma
Cancer Type: Brain & Spinal Cord Tumor, Brain Tumor

PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
Cancer Type: Solid Tumor, Unknown Primary

Psilocybin Combined with Multidisciplinary Palliative Care in Demoralized Cancer Survivors with Chronic Pain
Cancer Type: Hematopoietic Malignancies, Solid Tumor

Radiation Medication (Radium-223 dichloride) versus Radium-223 dichloride plus Radiation Enhancing Medication (M3814) versus Radium-223 dichloride plus M3814 plus Avelumab (a type of immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
Cancer Type: Prostate Cancer

Radiation Therapy or Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed Anaplastic Glioma or Low Grade Glioma
Cancer Type: Brain & Spinal Cord Tumor, Brain Tumor

Radiation Therapy with or without Cisplatin in Treating Patients with Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Cancer Type: Head and Neck Cancer

Radioligand Therapy after PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients with Biochemically Recurrent Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
Cancer Type: Bile Duct Cancer, Liver Cancer / Hepatoblastoma, Solid Tumor, Unknown Primary

Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
Cancer Type: Brain & Spinal Cord Tumor

Registry Study for Radiation Therapy Outcomes
Cancer Type: Solid Tumor

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
Cancer Type: Liver Cancer / Hepatoblastoma, Unknown Primary

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Cancer Type: Gynecologic Cancers, Primary Peritoneal Cancer, Unknown Primary

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
Cancer Type: Ovarian Cancer, Unknown Primary

REtroperitoneal SArcoma Registry: an International Prospective Initiative
Cancer Type: Sarcoma

Rifaximin in Treating Patients with Monoclonal Gammopathy
Cancer Type: Multiple Myeloma, Plasma cell neoplasm

Rituximab with or without Stem Cell Transplant in Treating Patients with Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Robotic vs. Open NSM for Early Stage Breast Cancer
Cancer Type: Breast Cancer

Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination
Cancer Type: Hematopoietic Malignancies, Solid Tumor

Sirolimus and Metronomic Chemotherapy for the Treatment of High-Risk Solid Tumors in Children, AflacST1903 Study
Cancer Type: Sarcoma, Solid Tumor

Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab for the Treatment of Locally Advanced or Metastatic Cancer
Cancer Type: Solid Tumor, Unknown Primary

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors with NovoTTF-200M for the Treatment of Melanoma Brain Metastases
Cancer Type: Melanoma

Stereotactic Radiosurgery or Hippocampus Avoidance Whole-Brain Radiation Therapy with Memantine in Treating Patients with 5 or more Brain Metastases
Cancer Type: Brain & Spinal Cord Tumor, Unknown Primary

Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
Cancer Type: Lung Cancer

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Cancer Type: Prostate Cancer

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
Cancer Type: Leukemia, Multiple Myeloma, Plasma cell neoplasm

Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia
Cancer Type: Leukemia

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Cancer Type: Leukemia

Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
Cancer Type: Lung Cancer, Melanoma

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Cancer Type: Lung Cancer, Melanoma, Stomach/ Gastric Cancer

Study of INCB123667 in Subjects With Advanced Solid Tumors
Cancer Type: Solid Tumor, Unknown Primary

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
Cancer Type: Neuroendocrine Tumor, Pancreatic Cancer, Unknown Primary

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Cancer Type: Unknown Primary

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Cancer Type: Breast Cancer, Unknown Primary

Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
Cancer Type: Head and Neck Cancer, Sarcoma

Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
Cancer Type: Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)

Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
Cancer Type: Brain & Spinal Cord Tumor, Hematopoietic Malignancies, Lymphoma, Unknown Primary

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Cancer Type: Kidney Cancer, Unknown Primary

Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer
Cancer Type: Solid Tumor, Unknown Primary

Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Cancer Type: Multiple Myeloma, Plasma cell neoplasm

Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy
Cancer Type: Hematopoietic Malignancies, Solid Tumor

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type: Multiple Myeloma, Non-Hodgkin Lymphoma, Plasma cell neoplasm

TAS102 and Liposomal Irinotecan in Treating Patients with Gastrointestinal Cancers That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Cancer Type: Bile Duct Cancer

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Cancer Type: Head and Neck Cancer, Unknown Primary

Testing Drug Treatments after CAR T-cell Therapy in Patients with Diffuse Large B-cell Lymphoma That Has Come Back or Not Responded to Treatment
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Testing Immunotherapy versus Observation in Patients with HPV Throat Cancer
Cancer Type: Head and Neck Cancer, Unknown Primary

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
Cancer Type: Kidney Cancer

Testing the Addition of a Blood Pressure Medication, Carvedilol, to HER-2 Targeted Therapy for Metastatic Breast Cancer to Prevent Cardiac Toxicity
Cancer Type: Breast Cancer

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) after Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation
Cancer Type: Colon/Rectal Cancer, Unknown Primary

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors that have Returned after Previous Treatment
Cancer Type: Brain & Spinal Cord Tumor, Unknown Primary

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy before Surgery for Patients with High-Grade Upper Urinary Tract Cancer
Cancer Type: Unknown Primary

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Cancer Type: Lung Cancer

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients with Advanced Solid Tumors, The ComBET Trial
Cancer Type: Solid Tumor, Unknown Primary

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Cancer Type: Bladder Cancer, Kidney Cancer, Penile Cancer, Urethral Cancer

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), The ARCHON-1 Trial
Cancer Type: Lung Cancer

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
Cancer Type: Colon/Rectal Cancer, Unknown Primary

Testing the Use of Chemotherapy after Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Cancer Type: Neuroendocrine Tumor, Unknown Primary

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab with or without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
Cancer Type: Head and Neck Cancer

The Use of the LuViva Advanced Cervical Scan to Identify Women at High-Risk for Cervical Neoplasia
Cancer Type: Unknown Primary

Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients with Stage I-III Early Stage Breast Cancer
Cancer Type: Breast Cancer

Treatment Response and Biomarker-Guided Steroid Taper for Children with GVHD
Cancer Type: Unknown Primary

Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Tumor Treating Fields for the Treatment of Brainstem Gliomas
Cancer Type: Brain & Spinal Cord Tumor

Venetoclax and Tocilizumab for the treatment of Patients with Relapsed or Refractory t(11;14) Multiple Myeloma
Cancer Type: Multiple Myeloma

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
Cancer Type: Hematopoietic Malignancies, Unknown Primary

Vidutolimod (CMP-001) in Combination with Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas
Cancer Type: Brain & Spinal Cord Tumor

Vorinostat in Preventing Graft Versus Host Disease in Children, Adolescents, and Young Adults Undergoing Blood and Bone Marrow Transplant
Cancer Type: Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma

Vudalimab in Combination with Standard of Care Treatment in Patients with Metastatic Castration Sensitive Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
Cancer Type: Lymphoma, Non-Hodgkin Lymphoma
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.